Get the Stockscreener App
76.09
4.06%
2.97
After Hours:
76.09
Ionis Pharmaceuticals Inc stock is traded at $76.09, with a volume of 2.08M.
It is up +4.06% in the last 24 hours and up +6.21% over the past month.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
See More
Previous Close:
$73.12
Open:
$73
24h Volume:
2.08M
Relative Volume:
0.75
Market Cap:
$12.32B
Revenue:
$705.14M
Net Income/Loss:
$-453.90M
P/E Ratio:
-25.03
EPS:
-3.04
Net Cash Flow:
$-551.29M
1W Performance:
+6.35%
1M Performance:
+6.21%
6M Performance:
+127.13%
1Y Performance:
+124.19%
1-Day Range:
$73.00
$76.31
1-Week Range:
$70.69
$76.31
52-Week Range:
$23.95
$76.78
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
76.09 | 11.84B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-26-25 | Upgrade | Goldman | Sell → Neutral |
| Sep-03-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-31-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-01-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-07-25 | Initiated | H.C. Wainwright | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Neutral |
| Aug-02-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-16-24 | Resumed | Jefferies | Buy |
| Jun-14-24 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-10-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Sep-29-23 | Initiated | Raymond James | Strong Buy |
| Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
| Jun-07-23 | Resumed | Piper Sandler | Overweight |
| May-04-23 | Upgrade | Citigroup | Sell → Neutral |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-09-22 | Resumed | Morgan Stanley | Overweight |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-01-22 | Initiated | Citigroup | Sell |
| Mar-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-07-21 | Upgrade | UBS | Sell → Neutral |
| Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-16-20 | Initiated | UBS | Sell |
| Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Sep-02-20 | Initiated | The Benchmark Company | Hold |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-08-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Reiterated | Stifel | Hold |
| May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-06-17 | Resumed | Goldman | Sell |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Aug-09-17 | Reiterated | Stifel | Hold |
| Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
| Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
| Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
Can Ionis Pharmaceuticals Inc. (ISI) stock sustain revenue momentumFed Meeting & Daily Oversold Bounce Ideas - newser.com
Is Ionis Pharmaceuticals Inc. stock a defensive play in 2025Weekly Trading Summary & Weekly Return Optimization Plans - newser.com
Insider Sell: Joan Herman Sells 44,000 Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus
Can Ionis Pharmaceuticals Inc. (ISI) stock stage a strong rebound this quarterWeekly Volume Report & Weekly Breakout Opportunity Watchlist - newser.com
Is Ionis Pharmaceuticals Inc. (ISI) stock undervalued after correctionWatch List & Fast Entry Momentum Alerts - newser.com
Will Ionis Pharmaceuticals Inc. stock pay special dividendsJuly 2025 Sector Moves & Safe Swing Trade Setups - newser.com
Arrowhead’s Redemplo Approval Sets Up Standoff With Ionis’s Tryngolza - Citeline News & Insights
How Ionis Pharmaceuticals Inc. stock trades during market volatilityQuarterly Profit Report & AI Driven Price Forecasts - newser.com
Why Ionis Pharmaceuticals Inc. stock attracts high net worth investorsWeekly Profit Analysis & Real-Time Chart Pattern Alerts - newser.com
Arrowhead Pharmaceuticals Steps Into The Rare Disease Market - Finimize
Price momentum metrics for Ionis Pharmaceuticals Inc. explained2025 Market Outlook & Intraday High Probability Setup Alerts - newser.com
Is Ionis Pharmaceuticals Inc. (ISI) stock attractive post correctionPortfolio Gains Report & Consistent Profit Trade Alerts - newser.com
How Ionis Pharmaceuticals Inc. (ISI) stock compares with tech leaders2025 Momentum Check & Stock Portfolio Risk Management - newser.com
With FDA Approval for RNAi Drug, Arrowhead Pharma Starts Price War With Rival Ionis - MedCity News
US FDA approves Arrowhead's genetic disorder drug - Reuters
Arrowhead’s plozasiran cleared for FCS; Ionis patent duel awaits - BioWorld MedTech
RNAi biotech Arrowhead wins first FDA approval - BioPharma Dive
Ionis Pharmaceuticals Completes $770M Convertible Notes Offering - TipRanks
Ionis Pharmaceuticals (IONS) Price Target Increased by 10.27% to 85.25 - Nasdaq
Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead (NASDAQ:ARWR) - Seeking Alpha
Ionis Pharmaceuticals (BIT:1IONS) Price Target Increased by 10.16% to 73.30 - Nasdaq
DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE) - BioSpace
Can Ionis Pharmaceuticals Inc. stock sustain free cash flow growthTrade Signal Summary & Risk Adjusted Buy and Sell Alerts - newser.com
What Recent Clinical Trial Updates Mean for Ionis Pharmaceuticals Stock Valuation in 2025 - Yahoo Finance
Will Ionis Pharmaceuticals Inc. stock deliver better than expected guidanceTrade Signal Summary & Expert Approved Momentum Ideas - newser.com
Biogen Completes Acquisition of Alcyone Therapeutics - Benzinga
Ionis Pharmaceuticals stock rises after positive EU regulatory opinion By Investing.com - Investing.com India
Ionis Pharmaceuticals stock rises after positive EU regulatory opinion - Investing.com
Sanofi, Lilly among winners of EU drug recommendations this week - Seeking Alpha
Ionis Pharmaceuticals (IONS) Advances with European Review for D - GuruFocus
Is Ionis Pharmaceuticals Inc. stock in correction or buying zone2025 Market WrapUp & Intraday High Probability Alerts - Fundação Cultural do Pará
Ionis Pharmaceuticals Says Dawnzera Recommended for Approval in EU for Hereditary Angioedema - MarketScreener
EU committee recommends approval of Ionis’ HAE treatment By Investing.com - Investing.com Canada
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):